medicaid glp-1 coverage Did you know? Approximately 36% of Ohioans are dealing with obesity. Addressing this challenge requires modern, science-based solutions. medications are helping patients reduce weight, lower their risk of chronic disease, and ๐ข New Resource Alert! We've
Description
Obesity GLP-1 Market Value Chain Analysis Who are the Major Players in the Global Obesity GLP-1 Market
Interesting mix of findings

Remaining Challenges in ePA for GLP-1s While ePA greatly reduces friction, some challenges remain: Incomplete Payer Connectivity: Not every insurer will accept ePA for every drug/plan

Moreover, fourteen articles had an unclear risk of selection bias for random sequence generation and allocation concealment [11, 15, 19, 24, 26, 27, 30, 32, 3942, 46, 47], thirteen articles presented unclear risk of bias for blinding [15, 19, 24, 28, 31, 32, 3638, 41, 44, 46, 47], while three articles showed an unclear risk for attrition bias, reporting bias and other sources of bias [23, 27, 31]

These potential confounders were identified by Read and SNOMED-CT codes in the CPRD and ICD-10 codes in HES APC
